- Home
- South East Asia Molecular Point Of Care Testing Using Naat Market
South East Asia Molecular Point of Care Testing (Using NAAT) Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-166 | No of pages: 324 | Format:
South East Asia molecular point of care testing (using NAAT) market is projected to register a substantial CAGR of 8.9% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020, and the forecast period is 2021 to 2028.
Market Segmentation:
South East Asia Molecular Point of Care Testing (Using NAAT), By Product (Instruments And Consumables And Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing And Others), End User ( Laboratories, Hospitals, Clinics, Home Care, Ambulatory Centers, Assisted Living Facilities And Others), Mode Of Testing ( Prescription-Based Testing And OTC-Based Testing), Distribution Channel (Direct Sales, Third Party Distributors, Online Sales), Country (Singapore, Vietnam, Thailand, Philippines, Indonesia and Rest of South East Asia), Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the South East Asia molecular point of care testing (using NAAT) market are:
Improving diagnosis seeking rate
Increasing disposable income
Market Players:
Some of the key market players for South East Asia molecular point of care testing (using NAAT) market are listed below:
Danaher
Thermo Fisher Scientific Inc.
Hologic, Inc.
BD
F. Hoffmann-La Roche Ltd
ABBOTT
Seegene Inc.
bioMrieux SA
QIAGEN
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Grifols, S.A.
Quidel Corporation
GenMark Diagnostics, Inc.
SD Biosensor, INC.
Oxford Nanopore Technologies
Wondfo
Randox Laboratories Ltd.
Meridian Bioscience
QuantuMDx Group Ltd.
Lucira Health Inc.
Co-Diagnostics, Inc.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF SOUTH ASIA & SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 42
1.4 LIMITATIONS 44
1.5 MARKETS COVERED 44
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.7 MULTIVARIATE MODELLING 53
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 56
2.11 MARKET END USER COVERAGE GRID 57
2.12 SECONDARY SOURCES 58
2.13 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 62
4.1 PORTERS FIVE FORCES 63
4.2 PESTEL ANALYSIS 64
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES 65
4.3.1 CEPHEID 65
4.3.2 THERMO FISHER SCIENTIFIC INC. 66
4.3.3 HOLOGIC, INC. 67
4.3.4 BD 68
4.3.5 F. HOFFMANN-LA ROCHE LTD 69
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY 70
4.5 PRICE PER POCT INSTRUMENT 71
4.5.1 NORTH AMERICA 71
4.5.2 EUROPE 73
4.5.3 SOUTH ASIA 74
4.5.4 SOUTH EAST ASIA 76
4.5.5 MIDDLE EAST 79
4.5.6 AFRICA 81
4.6 PRICE PER TEST 83
4.6.1 NORTH AMERICA 83
4.6.2 EUROPE 91
4.6.3 SOUTH ASIA 99
4.6.4 SOUTH EAST ASIA 107
4.6.5 MIDDLE EAST 119
4.6.6 AFRICA 131
4.7 MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS 139
4.8 MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) 143
4.9 MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS 147
4.10 MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS 150
4.11 DISTRIBUTORS 153
4.11.1 NORTH AMERICA 153
4.11.2 EUROPE 154
4.11.3 SOUTH ASIA 156
4.11.4 SOUTH EAST ASIA 157
4.11.5 MIDDLE EAST 159
4.11.6 AFRICA 160
5 REGULATORY FRAMEWORK 161
6 MARKET OVERVIEW 164
6.1 DRIVERS 166
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 166
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE 166
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 167
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE 167
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING 168
6.2 RESTRAINTS 169
6.2.1 PRODUCT RECALLS 169
6.2.2 HIGH COSTS OF PRODUCTS 169
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS 170
6.3 OPPORTUNITIES 170
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 170
6.3.2 RISING HEALTHCARE EXPENDITURE 171
6.3.3 PANDEMIC OUTBREAK OF COVID-19 172
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 172
6.4 CHALLENGES 173
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES 173
6.4.2 LACK OF ACCESSIBILITY 173
7 IMPACT OF COVID-19 ON THE SOUTH ASIA & SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 175
7.1 IMPACT ON PRICE 175
7.2 IMPACT ON DEMAND 175
7.3 IMPACT ON SUPPLY CHAIN 176
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19 176
7.5 CONCLUSION: 177
8 SOUTH ASIA & SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT 178
8.1 OVERVIEW 179
8.2 CONSUMABLES & REAGENTS 182
8.3 INSTRUMENTS 182
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE) 183
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM) 183
9 SOUTH ASIA & SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION 184
9.1 OVERVIEW 185
9.2 RESPIRATORY INFECTIONS TESTING 188
9.2.1 COVID-19 189
9.2.2 FLU B 189
9.2.3 FLU A 189
9.2.4 RSV 189
9.2.5 TUBERCULOSIS 189
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA) 189
9.2.7 OTHERS 190
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING 190
9.3.1 TV 191
9.3.2 CT 191
9.3.3 NG 191
9.3.4 HPV 191
9.3.5 HSV 191
9.3.6 MG 191
9.3.7 UU 192
9.3.8 MH 192
9.3.9 OTHERS 192
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING 192
9.4.1 GROUP B STREPTOCOCCUS 193
9.4.2 SHIGA TOXIN 193
9.4.3 H. PYLORI 193
9.5 OTHERS 194
10 SOUTH ASIA & SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER 195
10.1 OVERVIEW 196
10.2 LABORATORIES 199
10.3 HOSPITAL 199
10.4 CLINICS 200
10.5 AMBULATORY CENTER 201
10.6 HOMECARE 201
10.7 ASSISTED LIVING FACILITIES 202
10.8 OTHERS 203
11 SOUTH ASIA & SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING 204
11.1 OVERVIEW 205
11.2 PRESCRIPTION-BASED TESTING 208
11.3 OTC TESTING 209
12 SOUTH ASIA & SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL 210
12.1 OVERVIEW 211
12.2 DIRECT SALES 214
12.3 THIRD PARTY DISTRIBUTOR 214
12.4 ONLINE SALES 215
13 SOUTH ASIA & SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 216
13.1 SOUTH ASIA 217
13.1.1 INDIA 225
13.1.2 PAKISTAN 229
13.1.3 BANGLADESH 233
13.1.4 REST OF SOUTH ASIA 237
13.2 SOUTH EAST ASIA 238
13.2.1 SINGAPORE 246
13.2.2 VIETNAM 250
13.2.3 THAILAND 254
13.2.4 MALAYSIA 258
13.2.5 INDONESIA 261
13.2.6 PHILIPPINES 265
13.2.7 REST OF SOUTH EAST ASIA 269
14 SOUTH ASIA & SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE 270
14.1 COMPANY SHARE ANALYSIS: SOUTH ASIA & SOUTH EAST ASIA 270
15 SWOT ANALYSIS 271
16 COMPANY PROFILE 272
16.1 DANAHER 272
16.1.1 COMPANY SNAPSHOT 272
16.1.2 REVENUE ANALYSIS 272
16.1.3 COMPANY SHARE ANALYSIS 273
16.1.4 PRODUCT PORTFOLIO 273
16.1.5 RECENT DEVELOPMENTS 274
16.2 THERMO FISHER SCIENTIFIC INC. 275
16.2.1 COMPANY SNAPSHOT 275
16.2.2 REVENUE ANALYSIS 275
16.2.3 COMPANY SHARE ANALYSIS 276
16.2.4 PRODUCT PORTFOLIO 276
16.2.5 RECENT DEVELOPMENTS 276
16.3 HOLOGIC, INC. 277
16.3.1 COMPANY SNAPSHOT 277
16.3.2 REVENUE ANALYSIS 277
16.3.3 COMPANY SHARE ANALYSIS 278
16.3.4 PRODUCT PORTFOLIO 278
16.3.5 RECENT DEVELOPMENTS 278
16.4 BD 279
16.4.1 COMPANY SNAPSHOT 279
16.4.2 REVENUE ANALYSIS 279
16.4.3 COMPANY SHARE ANALYSIS 280
16.4.4 PRODUCT PORTFOLIO 280
16.4.5 RECENT DEVELOPMENTS 280
16.5 F.HOFFMANN-LA-ROCHE LTD. 281
16.5.1 COMPANY SNAPSHOT 281
16.5.2 REVENUE ANALYSIS 281
16.5.3 COMPANY SHARE ANALYSIS 282
16.5.4 PRODUCT PORTFOLIO 282
16.5.5 RECENT DEVELOPMENTS 283
16.6 ABBOTT 284
16.6.1 COMPANY SNAPSHOT 284
16.6.2 REVENUE ANALYSIS 284
16.6.3 PRODUCT PORTFOLIO 285
16.6.4 RECENT DEVELOPMENTS 285
16.7 BINX HEALTH, INC. 286
16.7.1 COMPANY SNAPSHOT 286
16.7.2 PRODUCT PORTFOLIO 286
16.7.3 RECENT DEVELOPMENT 286
16.8 BIOMERIEUX SA 287
16.8.1 COMPANY SNAPSHOT 287
16.8.2 REVENUE ANALYSIS 287
16.8.3 PRODUCT PORTFOLIO 288
16.8.4 RECENT DEVELOPMENT 288
16.9 BIO-RAD LABORATORIES, INC. 289
16.9.1 COMPANY SNAPSHOT 289
16.9.2 REVENUE ANALYSIS 289
16.9.3 PRODUCT PORTFOLIO 290
16.9.4 RECENT DEVELOPMENTS 290
16.10 CO-DIAGNOSTICS, INC. 292
16.10.1 COMPANY SNAPSHOT 292
16.10.2 REVENUE ANALYSIS 292
16.10.3 PRODUCT PORTFOLIO 293
16.10.4 RECENT DEVELOPMENTS 293
16.11 GENMARK DIAGNOSTICS, INC 294
16.11.1 COMPANY SNAPSHOT 294
16.11.2 REVENUE ANALYSIS 294
16.11.3 PRODUCT PORTFOLIO 295
16.11.4 RECENT DEVELOPMENT 295
16.12 GRIFOLS, S.A. 296
16.12.1 COMPANY SNAPSHOT 296
16.12.2 REVENUE ANALYSIS 296
16.12.3 PRODUCT PORTFOLIO 297
16.12.4 RECENT DEVELOPMENT 297
16.13 LUCIRA HEALTH INC. 298
16.13.1 COMPANY SNAPSHOT 298
16.13.2 PRODUCT PORTFOLIO 298
16.13.3 RECENT DEVELOPMENTS 298
16.14 MERIDIAN BIOSCIENCE 299
16.14.1 COMPANY SNAPSHOT 299
16.14.2 REVENUE ANALYSIS 299
16.14.3 PRODUCT PORTFOLIO 300
16.14.4 RECENT DEVELOPMENTS 300
16.15 OXFORD NANOPORE TECHNOLOGIES 301
16.15.1 COMPANY SNAPSHOT 301
16.15.2 PRODUCT PORTFOLIO 301
16.15.3 RECENT DEVELOPMENT 301
16.16 PERKIN ELMER INC. 302
16.16.1 COMPANY SNAPSHOT 302
16.16.2 REVENUE ANALYSIS 302
16.16.3 PRODUCT PORTFOLIO 303
16.16.4 RECENT DEVELOPMENT 303
16.17 QIAGEN 304
16.17.1 COMPANY SNAPSHOT 304
16.17.2 REVENUE ANALYSIS 304
16.17.3 PRODUCT PORTFOLIO 305
16.17.4 RECENT DEVELOPMENTS 305
16.18 QUANTUMDX GROUP LTD. 307
16.18.1 COMPANY SNAPSHOT 307
16.18.2 PRODUCT PORTFOLIO 307
16.18.3 RECENT DEVELOPMENTS 307
16.19 QUIDEL CORPORATION 309
16.19.1 COMPANY SNAPSHOT 309
16.19.2 REVENUE ANALYSIS 309
16.19.3 PRODUCT PORTFOLIO 310
16.19.4 RECENT DEVELOPMENT 310
16.20 RANDOX LABORATORIES LTD. 311
16.20.1 COMPANY SNAPSHOT 311
16.20.2 PRODUCT PORTFOLIO 311
16.20.3 RECENT DEVELOPMENTS 311
16.21 SD BIOSENSOR, INC. 313
16.21.1 COMPANY SNAPSHOT 313
16.21.2 PRODUCT PORTFOLIO 313
16.21.3 RECENT DEVELOPMENT 313
16.22 SEEGENE INC, 314
16.22.1 COMPANY SNAPSHOT 314
16.22.2 REVENUE ANALYSIS 314
16.22.3 PRODUCT PORTFOLIO 315
16.22.4 RECENT DEVELOPMENT 315
16.23 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL) 316
16.23.1 COMPANY SNAPSHOT 316
16.23.2 PRODUCT PORTFOLIO 316
16.23.3 RECENT DEVELOPMENT 316
16.24 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION 318
16.24.1 COMPANY SNAPSHOT 318
16.24.2 REVENUE ANALYSIS 318
16.24.3 PRODUCT PORTFOLIO 319
16.24.4 RECENT DEVELOPMENT 319
16.25 WONDFO 320
16.25.1 COMPANY SNAPSHOT 320
16.25.2 PRODUCT PORTFOLIO 320
16.25.3 RECENT DEVELOPMENT 320
17 QUESTIONNAIRE 321
18 RELATED REPORTS 324
Segmentation
Short Description
South East Asia Molecular Point of Care Testing (Using NAAT), By Product (Instruments And Consumables And Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing And Others), End User ( Laboratories, Hospitals, Clinics, Home Care, Ambulatory Centers, Assisted Living Facilities And Others), Mode Of Testing ( Prescription-Based Testing And OTC-Based Testing), Distribution Channel (Direct Sales, Third Party Distributors, Online Sales), (Singapore, Vietnam, Thailand, Philippines, Indonesia and Rest of South East Asia), Industry Trends and Forecast to 2028
Market Definition
Point of Care Testing (POCT) is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering into clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically in the range of 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30x30cm. These instruments are essentially used in the molecular detection of various disorders such as HIV, HPV, and respiratory disease through nucleic acid amplification techniques (NAAT) technology. NAAT allows the identification of pathogenic organisms by detecting their DNA or RNA.
In the global pandemic, attempt to synergize the sensitivity of NAATs and the ease of use of POCT assays, miniaturized NAAT-based POCT devices and assays were devised for faster screening and diagnosis of COVID-19, which also propel the growth of the market.
Molecular point-of-care testing's significant advantages include the rapid diagnosis process, treatment choice, monitoring, and prognosis. This will also help in operational decision-making and proper resource utilization.
Market Segmentation
South East Asia molecular point of care testing (using NAAT) market is categorized into five notable segments which are based on product, indication, end user, mode of testing, and distribution channel.
On the basis of product, the South East Asia molecular point of care testing (using NAAT) market is segmented into instruments, consumables, and reagents
On the basis of indication, the South East Asia molecular point of care testing (using NAAT) market is segmented into sexually transmitted infection (STI) testing, respiratory infection testing, gastrointestinal tract infection testing, and others
On the basis of end user, the South East Asia molecular point of care testing (using NAAT) market is segmented into laboratories, hospitals, clinics, ambulatory centers, home care, assisted living facilities, and others
On the basis of mode of testing, the South East Asia molecular point of care testing (using NAAT) market is segmented into prescription-based testing and OTC testing
On the basis of distribution channel, the South East Asia molecular point of care testing (using NAAT) market is segmented into direct tender, third party distributor, online sales
Market Players
Some of the key market players for South East Asia molecular point of care testing (using NAAT) market are listed below:
Danaher
Thermo Fisher Scientific Inc.
Hologic, Inc.
BD
F. Hoffmann-La Roche Ltd
ABBOTT
Seegene Inc.
bioMrieux SA
QIAGEN
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Grifols, S.A.
Quidel Corporation
GenMark Diagnostics, Inc.
SD Biosensor, INC.
Oxford Nanopore Technologies
Wondfo
Randox Laboratories Ltd.
Meridian Bioscience
QuantuMDx Group Ltd.
Lucira Health Inc.
Co-Diagnostics, Inc.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.